J. Goldman & CO LP Syndax Pharmaceuticals Inc Transaction History

J. Goldman & CO LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$6.93 - $14.63 $273,998 - $578,440	-39,538 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$8.71 - $14.82 $274,034 - $466,266	-31,462 Reduced 44.31%	39,538 $563,000
Q4 2017 Feb 14, 2018	BUY	$7.8 - $12.94 $148,200 - $245,860	19,000 Added 36.54%	71,000 $622,000
Q3 2017 Nov 14, 2017	BUY	$10.9 - $12.73 $566,800 - $661,960	52,000	52,000 $608,000

232

96.9M

1.39M

543K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $927M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.